Induction of differentiation in human myeloid leukemia cells with cytosine arabinoside. 1986

M Beran, and W N Hittelman, and B S Andersson, and K B McCredie

Normalization of granulocyte counts was obtained with low-dose cytosine arabinoside (Ara-C) in a patient with acute myelogenous leukemia (AML, FAB-M2) who had relapsed on maintenance therapy containing conventional doses of Ara-C and was clinically resistant to high-dose Ara-C treatment. The patient's leukemic cells exhibited an abnormal karyotype (45, X-Y, t[8q; 21q]). To determine whether the response to low-dose Ara-C was a result of induced leukemic cell differentiation, the mature peripheral blood granulocytes were isolated and fused with mitotic chinese hamster ovary (CHO) cells to induce premature chromosome condensation. Karyotypic evaluation of the granulocyte prematurely condensed chromosomes (PCC) during response to low-dose Ara-C demonstrated the presence of cells with 45 chromosomes. This result strongly suggests that part of this patient's response to low-dose Ara-C was a result of induced maturation of the leukemic clone.

UI MeSH Term Description Entries
D007621 Karyotyping Mapping of the KARYOTYPE of a cell. Karyotype Analysis Methods,Analysis Method, Karyotype,Analysis Methods, Karyotype,Karyotype Analysis Method,Karyotypings,Method, Karyotype Analysis,Methods, Karyotype Analysis
D007958 Leukocyte Count The number of WHITE BLOOD CELLS per unit volume in venous BLOOD. A differential leukocyte count measures the relative numbers of the different types of white cells. Blood Cell Count, White,Differential Leukocyte Count,Leukocyte Count, Differential,Leukocyte Number,White Blood Cell Count,Count, Differential Leukocyte,Count, Leukocyte,Counts, Differential Leukocyte,Counts, Leukocyte,Differential Leukocyte Counts,Leukocyte Counts,Leukocyte Counts, Differential,Leukocyte Numbers,Number, Leukocyte,Numbers, Leukocyte
D001854 Bone Marrow Cells Cells contained in the bone marrow including fat cells (see ADIPOCYTES); STROMAL CELLS; MEGAKARYOCYTES; and the immediate precursors of most blood cells. Bone Marrow Cell,Cell, Bone Marrow,Cells, Bone Marrow,Marrow Cell, Bone,Marrow Cells, Bone
D002454 Cell Differentiation Progressive restriction of the developmental potential and increasing specialization of function that leads to the formation of specialized cells, tissues, and organs. Differentiation, Cell,Cell Differentiations,Differentiations, Cell
D003561 Cytarabine A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472) Ara-C,Arabinofuranosylcytosine,Arabinosylcytosine,Cytosine Arabinoside,Aracytidine,Aracytine,Cytarabine Hydrochloride,Cytonal,Cytosar,Cytosar-U,beta-Ara C,Ara C,Arabinoside, Cytosine,Cytosar U,beta Ara C
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D015470 Leukemia, Myeloid, Acute Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES. Leukemia, Myelogenous, Acute,Leukemia, Nonlymphocytic, Acute,Myeloid Leukemia, Acute,Nonlymphocytic Leukemia, Acute,ANLL,Acute Myelogenous Leukemia,Acute Myeloid Leukemia,Acute Myeloid Leukemia with Maturation,Acute Myeloid Leukemia without Maturation,Leukemia, Acute Myelogenous,Leukemia, Acute Myeloid,Leukemia, Myeloblastic, Acute,Leukemia, Myelocytic, Acute,Leukemia, Myeloid, Acute, M1,Leukemia, Myeloid, Acute, M2,Leukemia, Nonlymphoblastic, Acute,Myeloblastic Leukemia, Acute,Myelocytic Leukemia, Acute,Myelogenous Leukemia, Acute,Myeloid Leukemia, Acute, M1,Myeloid Leukemia, Acute, M2,Nonlymphoblastic Leukemia, Acute,Acute Myeloblastic Leukemia,Acute Myeloblastic Leukemias,Acute Myelocytic Leukemia,Acute Myelocytic Leukemias,Acute Myelogenous Leukemias,Acute Myeloid Leukemias,Acute Nonlymphoblastic Leukemia,Acute Nonlymphoblastic Leukemias,Acute Nonlymphocytic Leukemia,Acute Nonlymphocytic Leukemias,Leukemia, Acute Myeloblastic,Leukemia, Acute Myelocytic,Leukemia, Acute Nonlymphoblastic,Leukemia, Acute Nonlymphocytic,Leukemias, Acute Myeloblastic,Leukemias, Acute Myelocytic,Leukemias, Acute Myelogenous,Leukemias, Acute Myeloid,Leukemias, Acute Nonlymphoblastic,Leukemias, Acute Nonlymphocytic,Myeloblastic Leukemias, Acute,Myelocytic Leukemias, Acute,Myelogenous Leukemias, Acute,Myeloid Leukemias, Acute,Nonlymphoblastic Leukemias, Acute,Nonlymphocytic Leukemias, Acute

Related Publications

M Beran, and W N Hittelman, and B S Andersson, and K B McCredie
August 1985, American journal of hematology,
M Beran, and W N Hittelman, and B S Andersson, and K B McCredie
January 1984, Leukemia research,
M Beran, and W N Hittelman, and B S Andersson, and K B McCredie
January 1986, Leukemia research,
M Beran, and W N Hittelman, and B S Andersson, and K B McCredie
July 2015, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,
M Beran, and W N Hittelman, and B S Andersson, and K B McCredie
June 1977, Clinical pharmacology and therapeutics,
M Beran, and W N Hittelman, and B S Andersson, and K B McCredie
September 1996, The international journal of biochemistry & cell biology,
M Beran, and W N Hittelman, and B S Andersson, and K B McCredie
July 2004, Leukemia,
M Beran, and W N Hittelman, and B S Andersson, and K B McCredie
August 1984, Ugeskrift for laeger,
M Beran, and W N Hittelman, and B S Andersson, and K B McCredie
August 2001, Leukemia research,
Copied contents to your clipboard!